Investor Overview

Webcast ImageWebcast
ASH 2017 Analyst Event (Replay)
12/10/17 at 8:15 p.m. ET
ASH 2017 Analyst Event
Sunday, December 10, 2017 8:15 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s product candidates seek to treat cancer by targeting malignant cells both directly and through modulation of the tumor microenvironment. The Company is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 3 registration trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and a Phase 2 study in refractory indolent Non-Hodgkin’s Lymphoma (iNHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018. Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.
Stock Quote
VSTM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.65
Change (%) Stock is Down 0.15 (3.95%)
Volume1,071,034
Data as of 12/14/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News More >>
DateTitle 
12/14/17Verastem Announces Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Dec. 14, 2017-- Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that it intends to offer and sell $25 million of its common stock in an underwritten public offering. All of the shares to be sold in the offering are to be sold by Verastem. BTIG, LLC is acting as sole book-running manager for the offering. ... 
Printer Friendly Version
12/11/17Verastem Announces the Presentation of Phase 1 Duvelisib Combination Data in T-Cell Lymphomas at the ASH 2017 Annual Meeting
Duvelisib Demonstrates an Acceptable Safety Profile in Combination with Romidepsin or Bortezomib in Patients with Relapsed/Refractory TCL Combination of Duvelisib and Romidepsin Achieves 60% Overall Response Rate Including a 27% Complete Response Rate in these patient populations BOSTON--(BUSINESS WIRE)--Dec. 11, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of ca... 
Printer Friendly Version
12/10/17Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The DUO Study Achieves Primary Endpoint, Demonstrating Statistically Significant Improvement in PFS for Duvelisib Versus Ofatumumab (HR=0.52, p<0.0001) Oral Duvelisib Monotherapy Also Achieves Significantly Higher ORR Compared to Ofatumumab (p<0.0001) Duvelisib Continues to Demonstrate a Consistent and Manageable Safety Profile BOSTON--(BUSINESS WIRE)--Dec. 10, 2017-- Verastem, Inc. (NASDAQ: VSTM), focused on disco... 
Printer Friendly Version
12/05/17Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017
Event and Live Webcast to be Held on December 10th at 8:15 PM ET in Atlanta BOSTON--(BUSINESS WIRE)--Dec. 5, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, will present clinical data from the Phase 3 DUO study evaluating the efficacy and safety of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocyti... 
Printer Friendly Version
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Verastem Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.